ABSTRACT
BACKGROUND: The purpose of this study was to determine the efficacy of a combination of gemcitabine and sirolimus in a mouse model of invasive bladder cancer. MATERIALS AND METHODS: Gemcitabine (50 mg/kg) and sirolimus (1.5 mg/kg) were administered to animals previously exposed to N-butyl-N-4(hydroxybutyl)nitrosamine in drinking water. Tumour development was determined by histopathological evaluation. RESULTS: Both drugs were well tolerated by animals. The incidence of lesions in mice treated with gemcitabine was lower in comparison to those not treated, however this result was not statistically significant. The incidence of invasive bladder cancer in animals treated with sirolimus was statistically lower (20%) than in animals not treated (54%) (p=0.008). The results indicate that this drug combination has no statistical significance on the development of pre-neoplastic urothelial lesions and had only a minor impact on invasive bladder cancer incidence in mice. CONCLUSION: The combination of gemcitabine and sirolimus had only a marginal impact on invasive bladder cancer in a mouse model.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Urinary Bladder Neoplasms/chemically induced , Urinary Bladder Neoplasms/drug therapy , Animals , Butylhydroxybutylnitrosamine/toxicity , Deoxycytidine/administration & dosage , Deoxycytidine/analogs & derivatives , Male , Mice , Mice, Inbred ICR , Neoplasm Invasiveness , Sirolimus/administration & dosage , Survival Rate , Treatment Outcome , Urinary Bladder Neoplasms/pathology , GemcitabineABSTRACT
La preservación de sangre y de sus derivados ha sido una constante en el desarrollo de los bancos de sangre modernos. Los dos métodos actualmente utilizados son la fase líquida y la criopreservación. Se revisaron las generalidades de cada uno de ellos, así como los cambios físicos ocurridos a los eritrocitos durante su almacenamiento
Subject(s)
Blood Banks , Cryopreservation/standards , Cryopreservation , ErythrocytesABSTRACT
La forma más habitual de almacenamiento de eritrocitos es en fase líquida. Durante el almacenamiento se producen cambios deletéreos que disminuyen la viabilidad y funcionalidad en el receptor y conllevan a efectos colaterales. Se revisaron los mecanismos que generan los cambios bioquímicos de los eritrocitos
